Asked by: Helen Goodman (Labour - Bishop Auckland)
Question to the Department for Exiting the European Union :
To ask the Secretary of State for Exiting the European Union, what discussions he has had with EU counterparts on whether the UK will pay the costs of transferring the European Medicines Agency elsewhere in the event of its headquarters leaving London.
Answered by Robin Walker
The Government is committed to ensuring a positive outcome for the UK life sciences and pharmaceuticals sector as we exit the European Union.
In the negotiations, the Government will discuss with the EU and Member States how best to continue to cooperate in the field of medicines regulation in the best interests of both the UK and EU. It would not be appropriate to pre-judge the outcome of the negotiations.
Asked by: Helen Goodman (Labour - Bishop Auckland)
Question to the Department for Exiting the European Union :
To ask the Secretary of State for Exiting the European Union, what the Government's objectives are for regulation for pharmaceuticals after the UK leaves the EU.
Answered by Robin Walker
The Government is committed to ensuring a positive outcome for the UK life sciences and pharmaceuticals sector as we exit the European Union.
In the negotiations, the Government will discuss with the EU and Member States how best to continue to cooperate in the field of medicines regulation in the best interests of both the UK and EU. It would not be appropriate to pre-judge the outcome of the negotiations.
Asked by: Helen Goodman (Labour - Bishop Auckland)
Question to the Department for Exiting the European Union :
To ask the Secretary of State for Exiting the European Union, what assessment he has made of the potential effect on the UK pharmaceutical industry of the UK no longer being part of the European Medicines Agency after the UK leaves the EU.
Answered by Robin Walker
The Government is committed to ensuring a positive outcome for the UK life sciences and pharmaceuticals sector as we exit the European Union.
In the negotiations, the Government will discuss with the EU and Member States how best to continue to cooperate in the field of medicines regulation in the best interests of both the UK and EU. It would not be appropriate to pre-judge the outcome of the negotiations.